Table 3.
Synopsis of the IgG autoantibody profile of the pemphigus vulgaris (PV) patients prior to rituximab (preRtx) treatment and at the time of clinical relapse (CR).
| IgG against extracellular subdomains of Dsg3 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dsg3EC1 | Dsg3EC2 | Dsg3EC3 | Dsg3EC4 | Dsg3EC5 | |||||||||||
| Time point | preRtx | 6 months | CR | preRtx | 6 months | CR | preRtx | 6 months | CR | preRtx | 6 months | CR | preRtx | 6 months | CR |
| PV3 (CR, months 12) | + | + | + | − | + | + | − | − | − | − | + | + | − | − | − |
| PV5 (CR, months 12) | − | − | − | − | − | + | + | − | + | + | + | + | − | − | − |
| PV6 (CR, months 12) | + | − | + | − | − | − | − | − | − | − | − | − | − | − | − |
| PV13 (CR, months 18) | + | − | + | − | − | − | − | − | − | + | − | + | − | − | − |
| PV19 (CR, months 18) | + | + | + | − | − | − | − | − | − | − | − | + | − | − | − |
| PV23 (CR, months 18) | − | − | + | − | − | − | − | − | − | + | + | + | + | − | − |